Teton Advisors Inc. Has $1.68 Million Stock Position in Integer Holdings Co. (NYSE:ITGR)

Teton Advisors Inc. lowered its stake in Integer Holdings Co. (NYSE:ITGR) by 21.8% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 17,000 shares of the medical equipment provider’s stock after selling 4,730 shares during the period. Teton Advisors Inc.’s holdings in Integer were worth $1,684,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. GSA Capital Partners LLP acquired a new position in shares of Integer during the 3rd quarter worth approximately $816,000. Dark Forest Capital Management LP grew its position in shares of Integer by 69.8% during the 3rd quarter. Dark Forest Capital Management LP now owns 11,984 shares of the medical equipment provider’s stock worth $940,000 after purchasing an additional 4,926 shares in the last quarter. Legacy Wealth Asset Management LLC acquired a new stake in shares of Integer during the 4th quarter worth approximately $239,000. Trust Point Inc. acquired a new stake in shares of Integer during the 4th quarter worth approximately $874,000. Finally, Nomura Holdings Inc. boosted its position in shares of Integer by 3.9% during the 3rd quarter. Nomura Holdings Inc. now owns 180,270 shares of the medical equipment provider’s stock worth $14,139,000 after acquiring an additional 6,731 shares in the last quarter. Institutional investors and hedge funds own 99.29% of the company’s stock.

Integer Trading Down 2.6 %

Shares of ITGR stock traded down $2.96 during trading hours on Tuesday, hitting $111.61. 453,253 shares of the company’s stock traded hands, compared to its average volume of 346,556. The stock’s 50 day simple moving average is $113.64 and its 200 day simple moving average is $100.61. The stock has a market cap of $3.74 billion, a PE ratio of 38.62, a price-to-earnings-growth ratio of 1.53 and a beta of 1.10. Integer Holdings Co. has a 12 month low of $69.40 and a 12 month high of $123.99. The company has a quick ratio of 2.01, a current ratio of 3.32 and a debt-to-equity ratio of 0.76.

Integer (NYSE:ITGR) last released its quarterly earnings results on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.02. Integer had a net margin of 6.01% and a return on equity of 11.25%. The firm had revenue of $414.80 million during the quarter, compared to the consensus estimate of $412.78 million. During the same quarter last year, the firm earned $0.87 earnings per share. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. On average, sell-side analysts anticipate that Integer Holdings Co. will post 5.27 EPS for the current year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ITGR. CL King began coverage on shares of Integer in a research report on Thursday, March 14th. They set a “buy” rating and a $137.00 price target on the stock. KeyCorp increased their price target on shares of Integer from $123.00 to $139.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 9th. Bank of America upgraded shares of Integer from a “neutral” rating to a “buy” rating and increased their price target for the stock from $105.00 to $135.00 in a research report on Monday, April 15th. Finally, Benchmark reissued a “buy” rating and issued a $130.00 price objective on shares of Integer in a research note on Friday. Three analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $120.50.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.